Page last updated: 2024-10-22

anastrozole and Pneumonia

anastrozole has been researched along with Pneumonia in 1 studies

Pneumonia: Infection of the lung often accompanied by inflammation.

Research Excerpts

ExcerptRelevanceReference
"Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression."9.69Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023)
"Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression."5.69Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Jerusalem, G1
Prat, A1
Salgado, R1
Reinisch, M1
Saura, C1
Ruiz-Borrego, M1
Nikolinakos, P1
Ades, F1
Filian, J1
Huang, N1
Mazzei-Abba, A1
Tolaney, SM1

Trials

1 trial available for anastrozole and Pneumonia

ArticleYear
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
    Breast (Edinburgh, Scotland), 2023, Volume: 72

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoad

2023